US

Board of Directors

Executive Directors

Alan Aubrey

Chief Executive Officer

Alan Aubrey

Chief Executive Officer

Alan was the joint founder and Chief Executive of Techtran Group Ltd, the first company in Europe to offer a complete outsourced technology transfer function to universities. Techtran was acquired by IP Group in 2005. From 1995-2002 Alan was a partner in KPMG where he specialised in providing advice to fast growing technology businesses. Alan holds a BA in Economics from the University of Leeds, an MBA with Distinction from the University of Bradford and is a fellow of the Institute of Chartered Accountants of England and Wales. Alan is also Non-Executive Chairman of Proactis Holdings plc, an AIM-listed software company based in York, and Non-executive Director of Oxford Sciences Innovation plc.

David Baynes

Chief Operating Officer

David Baynes

Chief Operating Officer

David was appointed to the Board in March 2014 following the acquisition of Fusion IP plc, where he was Chief Executive Officer and one of the founders. David had been a board director of Fusion IP plc since 2004, having been a director of Fusion IP Trading since 2003. Previously, David worked at Celsis International plc from its incorporation to its flotation on the full list of the London Stock Exchange in July 1993; Toad plc (now 21st Century Technology PLC), which he also co-founded where he was responsible for taking the company from start-up to a full listing on the London Stock Exchange. David was also CFO of Codemasters Limited, the UK's largest privately held games company.

Greg Smith

Chief Financial Officer

Greg Smith

Chief Financial Officer

Greg Smith joined IP Group as Group Financial Controller in January 2008 and was appointed Chief Financial Officer in June 2011. Previously Greg spent three years at Tarchon Capital Management, a multi-billion dollar fund of hedge funds business where he had day to day responsibility for building and managing the operations and accounting team as well as external operational due diligence on investee hedge funds. Prior to Tarchon, Greg spent four years in KPMG’s London Financial Services practice working with asset management, insurance and banking clients. Greg is a Chartered Accountant and holds a degree in Mathematics from the University of Warwick.

Mike Townend

Chief Investment Officer

Mike Townend

Chief Investment Officer

Mike joined IP Group's Board in 2007 from Lehman Brothers where he was Managing Director of European Equities and Head of Equity Sales to Hedge Funds. He has 17 years experience in all aspects of equity capital markets and the investment process and was also a key member of the senior relationship management programme at Lehman Brothers. Prior to this, he was an Executive Director at Donaldson, Lufkin and Jenrette with responsibility for building the bank’s business with hedge funds and alternatives. Mike has sourced, co-led or led numerous private and public transactions. He is the IP Group representative on the boards of Modern Water plc, Revolymer plc and Applied Graphene Materials plc. He is also a non-executive director of Green Urban Transport Ltd.

Non-executive Directors

Doug Liversidge, CBE

Senior Independent Director

Doug Liversidge, CBE

Senior Independent Director

Doug was appointed to the Board in March 2014 following IP Group's acquisition of Fusion IP plc, where he was Chairman. He became Senior Independent Director of IP Group in March 2015. Doug had been a board director of Fusion IP since 2004, having been a director of Fusion IP Trading since 2003. He was employed for 21 years at British Steel, before moving to G W Thornton Limited as Managing Director and subsequently Chief Executive. He guided the company through its flotation on the full list of the London Stock Exchange in March 1987. In 1991, Mr Liversidge was awarded South Yorkshire Businessman of the Year and was awarded the CBE in the 2000 New Year’s Honours List for services to industry. He is also Chairman of Surgical Innovations plc.

Dr Elaine Sullivan

Non-executive Director

Dr Elaine Sullivan

Non-executive Director

Dr Elaine Sullivan joined IP Group’s Board in 2015. She has over 25 years’ international experience in the pharmaceutical industry and was a member of senior management teams in R&D at Eli Lilly and AstraZeneca. From 2011 to 2015, Dr Sullivan was Vice President Global External Research & Development in the US for Eli Lilly, where she led a global workforce delivering access to business critical external innovation. Prior to this, she spent over 15 years at AstraZeneca where she held a number of roles including Vice President, Science & Technology, in which she identified and established novel drug-hunting approaches from target to delivery of proof of concept, and Vice President, R&D New Opportunities, establishing and leading the first virtual Therapy Area in AstraZeneca. In 2015, she founded a specialist oncology company, Carrick Therapeutics, and holds the position of Chief Executive. She is also a Member of the Supervisory Board of Evotec AG, a drug discovery solutions company.

Jonathan Brooks

Non-executive Director

Jonathan Brooks

Non-executive Director

Jonathan joined IP Group’s board in 2011 and is Chairman of the Group’s Audit Committee and Remuneration Committee. Jonathan was the Chief Financial Officer of ARM Holdings plc from 1995 until 2002 where he was responsible for finance, investor relations, legal and IT, and where he managed the IPO of ARM on both the London Stock Exchange and Nasdaq in 1998. He is a non-executive director of Aveva Group Plc, a provider of engineering data and design IT systems.

Mike Humphrey

Non-executive Chairman

Mike Humphrey

Non-executive Chairman

Mike Humphrey joined IP Group’s Board in 2011 and became Chairman in March 2015. Mike is the former CEO of Croda International plc. He was appointed to the Board of Croda in 1995 and became Group Chief Executive at the beginning of 1999. He joined Croda in 1969 as a management trainee and was appointed Managing Director of Croda Singapore in 1988, Croda Application Chemicals in 1990 and Croda Chemicals in 1991. He retired from Croda at the end of 2011.

Prof Lynn Gladden, CBE

Non-executive Director

Prof Lynn Gladden, CBE

Non-executive Director

Professor Gladden was appointed to the IP Group board in March 2014. She is Pro-Vice-Chancellor for Research for the University of Cambridge, the Shell Professor of Chemical Engineering and the former Head of the Department of Chemical Engineering and Biotechnology. She also serves as a Director of Cambridge Enterprise Limited, is a former member of the Council of the Engineering and Physical Sciences Research Council (EPSRC) and, in 2013, she was appointed to the Shell Science Council. She was Science Advisor to Unilever from 1998 – 2006 and a Senior Consultant to Physical & Engineering Sciences at Unilever from 2006-2008. She is a Fellow of the Royal Society, the Royal Academy of Engineering, the Institution of Chemical Engineers, the Royal Society of Chemistry and the Institute of Physics and is a chartered engineer and chartered chemist. Professor Gladden leads the activities at the Magnetic Resonance Research Centre at the University of Cambridge and has a particular interest in applying magnetic resonance imaging techniques in the fields of heterogeneous catalysis and multi-phase transport in porous media. She is a Fellow of Trinity College. She was awarded the 2014 Bakerian Lecture of the Royal Society and, in 2001, the Tilden lectureship and silver medal of the Royal Society of Chemistry. In 1996, she was awarded a Miller Visiting Professorship at the University of California, Berkeley and she received the Beilby Medal and Prize from the Royal Society of Chemistry in 1995. In 2013, Professor Gladden was awarded an Honorary Doctorate of Science from the University of Bristol and in 2009 she was awarded a CBE for services to chemical engineering following an OBE for services to chemistry in 2001. She is non-executive director of The British Land Company PLC.